(SOURCES: Feb. 6, 2008, teleconference with Elizabeth G. Nabel, M.D., director, U.S. National Heart, Lung, and Blood Institute; William Friedewald, M.D., clinical professor of public health and medicine, Columbia University, and chairman, ACCORD Steering Committee; Mary Ann Banerji, M.D., SUNY Downstate Medical Center, New York City; American Diabetes Association, news release, Feb. 6, 2008)
WEDNESDAY, Feb. 6 (HealthDay News) -- A large North American trial designed to aggressively lower the blood sugar of type 2 diabetics at risk of heart disease has been halted because of an unexpected number of deaths among those receiving the drug therapy.
Federal health officials announced Wednesday that 257 people who received the intensive therapy had died, compared with 203 in patients in a standard treatment group .....
Full Story